NCT03415477View on ClinicalTrials.gov

Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2017

Conditions
Bone Cyst AneurysmalPathological FractureRecurrent DiseaseRefractory Tumor
Interventions
DRUG

Denosumab (Xgeva)

Denosumab (Xgeva) 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day15 of the first cycle， perioperatively.

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT03415477 - Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts | Biotech Hunter | Biotech Hunter